{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:36:42Z","timestamp":1777934202124,"version":"3.51.4"},"reference-count":9,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2012,3,9]],"date-time":"2012-03-09T00:00:00Z","timestamp":1331251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2012,12]]},"abstract":"<jats:p>Lenalidomide is an immunomodulator used to treat 5q-myelodysplastic syndrome, myelofibrosis, and multiple myeloma. We describe a 55-year-old male who was started on lenalidomide 10\u2009mg daily for 21 days followed by 7 days off therapy for the treatment of early stage post-polycythemia vera myelofibrosis. Following initiation of lenalidomide, the patient was noted to have an asymptomatic increase in unconjugated bilirubin. Alkaline phosphatase, aspartate transaminase, and alanine aminotransferase were normal. During the 7 days off of lenalidomide, bilirubin began to trend down. Re-challenge with lenalidomide in subsequent cycles results in an asymptomatic elevation in unconjugated bilirubin followed by improvement during the 7-day lenalidomide-free period. The patient is a heterozygote for the TA7 allele which can decrease expression of uridine diphosphate glycuronosyl transferase 1A1, the enzyme responsible for conjugation of bilirubin. Therapy with lenalidomide may have unmasked Gilbert\u2019s syndrome in the patient.<\/jats:p>","DOI":"10.1177\/1078155212439492","type":"journal-article","created":{"date-parts":[[2012,3,9]],"date-time":"2012-03-09T23:23:41Z","timestamp":1331335421000},"page":"402-405","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":7,"title":["Lenalidomide-induced elevated bilirubin"],"prefix":"10.1177","volume":"18","author":[{"given":"Katherine A","family":"Simondsen","sequence":"first","affiliation":[{"name":"Department of Pharmacy, University of Wisconsin Hospital and Clinics, WI, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jill M","family":"Kolesar","sequence":"additional","affiliation":[{"name":"School of Pharmacy, University of Wisconsin, WI, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2012,3,9]]},"reference":[{"key":"bibr1-1078155212439492","unstructured":"Celgene Corporation. Lenalidomide (Revlamid) (package insert). Summit, NJ: Celgene Corporation, October 2010."},{"key":"bibr2-1078155212439492","first-page":"335","volume":"7","author":"Jain P","year":"2009","journal-title":"Blood Transfus"},{"key":"bibr3-1078155212439492","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-06-097758"},{"key":"bibr4-1078155212439492","doi-asserted-by":"publisher","DOI":"10.1159\/000326935"},{"key":"bibr5-1078155212439492","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2005.10.003"},{"key":"bibr6-1078155212439492","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154"},{"key":"bibr7-1078155212439492","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-200212000-00006"},{"key":"bibr8-1078155212439492","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpg.2010.07.007"},{"key":"bibr9-1078155212439492","doi-asserted-by":"publisher","DOI":"10.1097\/FPC.0b013e32834592fe"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155212439492","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1078155212439492","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155212439492","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:14:33Z","timestamp":1777688073000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1078155212439492"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3,9]]},"references-count":9,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["10.1177\/1078155212439492"],"URL":"https:\/\/doi.org\/10.1177\/1078155212439492","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,3,9]]}}}